

**Freedom of Information Act Disclosure log
- Reply Extract**

File reference	W21FOI 207
Key words	Disease Treatments and Patients Treated for Chronic Kidney Diseases
Date of release	13/08/2021
Attachments	No

You asked

Q1. How many patients have been treated in the last 6 months (for any disease) with the following products: 01/01/2021 – 30/06/2021

- **Aranesp & Aranesp SureClick (darbepoetin alpha) = 90 patients**
- **Eprex (epoetin alfa) = Five or fewer**
- **NeoRecormon (epoetin beta) = 0**
- **Retacrit (epoetin zeta) = Five or fewer**
- **Mircera (methoxy polyethylene glycol-epoetin beta) = 0**
- **Ferinject (ferric carboxymaltose injection/infusion) = 1197 patients**
- **Diafer (ferric derisomaltose injection) = 0**
- **Monofer (ferric derisomaltose injection) = 90 patients**
- **Cosmofer (iron dextran injection) = 0**
- **Venofer (iron sucrose injection) = 0**

Q2. In the past 6 months could you please state the number of patients treated for the following conditions:

- **Chronic kidney disease (ICD10 code – N.18) = 3383**
- **Chronic kidney disease - Stages 4 & 5 (ICD10 codes – N.18.3 & N.18.4 & N.18.5) = 2098**
- **Acquired cystic kidney disease (ICD10 code N28.1) = 191**
- **Chronic kidney disease – new patients (excluding previously treated patients) = The Trust does not record the information in this way.**
- **Acquired cystic kidney disease - new patients (excluding previously treated patients) = The Trust does not record the information in this way.**

Q3. Please indicate the number of patients treated in the last 6 months for chronic kidney disease ONLY with each of the following products:

- **Aranesp & Aranesp SureClick (darbepoetin alpha)**
- **Eprex (epoetin alfa)**
- **NeoRecormon (epoetin beta)**
- **Retacrit (epoetin zeta)**
- **Mircera (methoxy polyethylene glycol-epoetin beta)**
- **Ferinject (ferric carboxymaltose injection/infusion)**
- **Diafer (ferric derisomaltose injection)**
- **Monofer (ferric derisomaltose injection)**

- **Cosmofer (iron dextran injection)**
- **Venofer (iron sucrose injection)**

The Trust holds the information requested however could not retrieve it from the individual clinical records within the cost limit as defined by the act. Please refer to the legal notes below.

Legal notes

University Hospitals Plymouth NHS Trust is confirming in accordance with section 1 (a) of the Act that it holds the information requested and is supplying it in accordance with section 1(b) unless otherwise specified.

University Hospitals Plymouth NHS Trust (UPHT) is confirming in accordance with section 1 (a) of the Act that it does not hold the information requested in a structured manner. Individual records of how someone was treated and their conditions would be held in clinical records, but the Trust could not locate, extract and collate such information as requested within the limitations of the Act. Based on a rate of £25 per hour, in accordance with the Fees Regulations, we estimate that it will cost in excess of £450 to locate, retrieve and extract the information you have requested. This sum exceeds the appropriate limit of £450 as defined in the Freedom of Information and Data Protection (Appropriate Limit and Fees) Regulations 2004. It is therefore considered exempt from supply in accordance with section 12(1) of the Act – Request exceeds the appropriate limit by virtue of section 13.-(1)(a) – The Cost of Compliance exceeds the appropriate limit.

Attachments included: No